Eli Lilly is the GLP-1 Market Leader with Revenue of $125 Billion by 2030. Here's why the Stock Still has 50% Potential!

The battle for the crown in the GLP-1 products market is fierce. Eli Lilly appears to be the emerging winner. Eli Lilly solidifies its leadership position in the GLP-1 market through impressive clinical advancements. In September 2025, the study results of the oral tablet Orforglipron demonstrated superior performance in a direct comparison with the competing drug Semaglutide. The massive advantage is the daily tablet intake instead of an injection. To improve access and affordability in the USA, price reductions for key medications such as Zepbound...